Segments - Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 27, 2025	Sep. 28, 2024	Sep. 27, 2025	Sep. 28, 2024
Segment Reporting Information [Line Items]
Total net sales	$ 138,651	$ 138,964	$ 410,187	$ 419,638
Segment Adjusted EBITDA	26,604	23,557	79,567	80,632
Interest expense, net	(6,177)	(9,532)	(21,180)	(29,795)
Depreciation and amortization			(35,317)	(37,150)
Equity compensation	(3,176)	(2,491)	(8,951)
Loss on extinguishment	326	0	326	0
(Gain) loss on disposals	(1)	0	81	0
Impairment of assets			0	(33,901)
Income (loss) before income taxes	4,670	(5,259)	11,566	(52,289)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Interest expense, net	(6,177)	(9,532)	(21,180)	(29,795)
Depreciation and amortization	(11,403)	(12,275)	(35,317)	(37,150)
Acquisition and related costs		(483)		(994)
Shareholder litigation costs	(14)	(50)	(50)	(13,720)
Restructuring and succession charges		(54)		(67)
Equity compensation	(3,176)	(2,491)	(9,233)	(11,258)
Debt refinancing	(731)	(4)	(903)	(351)
Loss on extinguishment	(326)		(326)
(Gain) loss on disposals	1		(81)
Impairment of assets		(2,031)		(33,901)
Other items	(108)	(1,896)	(911)	(5,685)
US Segment \| Operating Segments
Segment Reporting Information [Line Items]
Total net sales	123,314	122,909	362,609	371,599
Adjusted cost of sales	28,537	29,703	82,152	85,173
Adjusted selling expense	37,917	38,670	109,984	114,400
Adjusted marketing expense	6,121	6,118	19,089	18,049
Adjusted general and administrative expense	24,401	25,322	72,509	73,275
Adjusted research and development expense	2,699	3,563	8,441	10,005
Adjusted other segment expense	200	(129)	1,465	(311)
Segment Adjusted EBITDA	23,439	19,662	68,969	71,008
International Segment \| Operating Segments
Segment Reporting Information [Line Items]
Total net sales	15,337	16,055	47,578	48,039
Adjusted cost of sales	5,890	5,504	17,797	17,643
Adjusted selling expense	2,943	2,823	9,362	8,372
Adjusted marketing expense	930	687	2,734	2,221
Adjusted general and administrative expense	2,389	3,639	6,874	10,250
Adjusted research and development expense	4	13	25	31
Adjusted other segment expense	16	(506)	188	(102)
Segment Adjusted EBITDA	$ 3,165	$ 3,895	$ 10,598	$ 9,624

Bioventus Inc. 10-Q